Early Cancer Detection using AI

Computer-aided diagnosis has developed from handcrafted image features and conventional classifiers toward deep neural networks that learn features directly from data. Convolutional neural networks (CNNs) are widely studied for image-based tasks, while transformer architectures and multimodal approaches are being explored for combining imaging with clinical context. In screening, an AI model may act as a triage aid, a second reader, or a quality-control tool. These roles are not interchangeable and require separate validation. 2.1 AI approaches Supervised learning: learns from labelled examples, such as images classified by a clinical reference standard. Deep learning: can identify complex spatial patterns in radiology, dermatology, endoscopy, or histopathology images. Risk modelling: uses structured variables such as age, family history, or laboratory results to estimate risk. Multimodal learning: combines imaging and clinical data when justified and securely available.

The central problem is how to design an AI-assisted system that can help flag potentially suspicious findings early while maintaining clinical safety, fairness, privacy, and understandable outputs. The system must avoid presenting predictions as definitive diagnoses and should direct uncertain or high-risk cases to qualified professionals.

The main objective is to define a reliable framework for evaluating AI as an aid to early cancer detection. Specific objectives are to: (i) describe a pipeline for collecting and preparing authorized data; (ii) select an appropriate model for a clearly defined cancer-detection task; (iii) assess performance using clinically meaningful metrics; (iv) include explanation and uncertainty information where technically appropriate; and (v) establish safeguards for privacy, bias, and clinician oversight. The proposed scope is a research prototype using appropriately de-identified, permissioned data. It does not provide individual medical advice, replace diagnostic tests, or independently determine treatment. A specific cancer type and modality must be selected before implementation because screening pathways and reference standards differ by disease.

The system is organized as a sequence of data governance, preprocessing, model inference, risk communication, and clinician review. Input could be a medical image or structured record depending on the selected use case. Data are checked for format, missing values, duplicates, image quality, and label consistency. A trained model generates a score or category; a separate decision layer applies a pre-defined threshold and flags uncertain cases. The output is shown with a concise explanation and the limitations of the model.

De-identified images / approved clinical variables ↓ 2. Data Quality & Preprocessing Quality checks

• normalization
• label review
• split by patient/site ↓

Model score + uncertainty / out-of-distribution check ↓

Flag for review

• explainable evidence
• limitations shown ↓ 5. Clinician Review & Follow-up Qualified professional decides next diagnostic step

Healthcare AI introduces risks that extend beyond model accuracy. False negatives may delay further investigation, while false positives may cause anxiety, additional testing, and unnecessary costs. The interface should communicate that an AI flag is not a diagnosis and should provide a clear route for human review. Clinical responsibility remains with qualified professionals.

Training data may underrepresent groups by age, sex, geography, skin tone, scanner type, or healthcare access. The development team should assess data coverage, document limitations, and report performance across clinically relevant subgroups where sample sizes permit. If a subgroup has insufficient evidence, the system should disclose that limitation rather than imply equivalent reliability.

Visual explanations or feature attributions can help reviewers inspect model behaviour, but they do not prove that a prediction is correct or that the model reasons clinically. Explanations should be evaluated with domain experts and presented as supporting information. The system should flag low-quality inputs, unfamiliar data, and uncertain predictions for manual review instead of forcing a confident classification.

This paper presented a conceptual framework for early cancer detection using AI, covering data governance, preprocessing, model inference, evaluation, clinician review, and post-deployment monitoring. AI may help identify suspicious patterns and prioritize cases, but it cannot independently establish a diagnosis. Reliable use requires representative data, external validation, explainable communication, privacy protections, and clear clinical accountability. Future work should select one cancer type and modality, obtain approved datasets, implement a baseline model, compare it with an appropriate reference standard, and conduct independent validation before considering clinical deployment.